Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the representatives of the nomination committee have been appointed ahead of the annual general meeting 2025. The nomination committee has been appointed in accordance with the principles for the nomination committee which were established by the annual general meeting on April 16, 2024.According to the principles for the nomination committee that were resolved at the annual general meeting on April 16, 2024, the nomination